Skip to main content

Plus Therapeutics Value Stock - Dividend - Research Selection

Plus Therapeutics

ISIN: US72941H4002, WKN: A2PPX6

Market price date: 27.05.2021
Market price: 2,35 USD




Plus Therapeutics Fundamental data and company key figures of the share

Annual reports in USD
Key figures 27-03-2021
Cash flow
Net operating cash flow -8.434.000
Capital Expenditures -493.000
Free cash flow -8.927.000
Balance sheet
Total Equity 3.031.000
Liabilities & Shareholders equity 12.105.000
Income statement
Net income -8.241.000
Eps (diluted) -1,860
Diluted shares outstanding 4.427.840
Net sales/revenue 303.000

Fundamental ratios calculated on: 27-05-2021

Ratios
Key figures 27-05-2021
Cash flow
P/C -1,20
   
P/FC -1,17
Balance sheet
ROI-68,08
ROE25,04
Income statement
P/E-1,26
Div. Yield0,00%
P/B3,35
P/S34,34


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolPSTV
Market Capitalization10.139.754,00 USD
Country
IndicesNO INDEX
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split2019-08-06,1.000000/50.000000; 2018-05-25,1.0000/10.0000; 2018-05-24,1.0000/10.0000; 2016-05-13,1.0000/15.0000; 2016-05-12,1.0000/15.0000
Internetwww.cytori.com


Description of the company

Cytori Therapeutics, Inc. develops cell therapies based on autologous adipose-derived stem and regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. The advanced therapeutic application in the Company´s clinical pipeline is for cardiovascular disease. The Company´s products include Celbrush, Puregraft, and Cytori LipoBank. The Celbrush is available in the 10 milliliter and 3 milliliter sizes and is used in conjunction with a Soft-Ject Syringe in the corresponding size. The Puregraft System is developed for autologous fat grafting and aesthetic body contouring. The Puregraft System is available in two sizes: 250 milliliter, which processes 50-250 milliliter of tissue, and 850 milliliter, which processes 200-850 milliliter of tissue. The Cytori LipoBank is a GTP-compliant cryopreservation system that offers a long-term storage option for viable adipose tissue after a single liposuction.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.cytori.com